Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality
CompletedPhase 2NCT00782795
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this study is to determine if study drug (Pioglitazone) treatment will improve pre-diabetes (insulin resistance) or ealy diabetes and improve clinical symptoms (pain) or laboratory evidence of chronic pancreatitis. The goal of the investigators is to gather information from this study to help gain understanding of a potential therapy for chronic pancreatitis.
Study details
- Official title
- Phase II Study of Chronic Pancreatitis and the Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality
- Conditions
- Chronic Pancreatitis
- Insulin Resistance
- Normal or Mildly Abnormal Stool Fat Levels
- Interventions
- Drug: Pioglitazone
- Drug: Placebo
- Sponsor
- University of Michigan
- Collaborators
- National Institute on Alcohol Abuse and Alcoholism (NIAAA); Takeda Pharmaceuticals North America, Inc.
- Start date
- 2008-11
- Primary completion
- 2013-12
- Sex
- All
- Age range
- from 18 Years to 75 Years
- Healthy volunteers
- true
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Insulin resistance or mild diabetes mellitus * Symptoms of abdominal pain * Xray test showing damage to the pancreas * Normal or mildly abnormal stool fat levels Exclusion Criteria: * Mentally disabled patients * Women who are planning pregnancy, pregnant or lactating/nursing * Chronic pancreatitis is due to other specific conditions * Autosomal dominant pancreatitis * Classic cystic fibrosis with lung involvement * Autoimmune pancreatitis * Pancreatic cancer * Biliary obstruction (non-pancreatic cause) * Abdominal trauma * Hypercalcemia * Hypertriglyceridemia * Surgical resection of the head of the pancreas * Alcohol consumption within prior 2 months * Specific medical conditions * Gastric surgery * Celiac sprue * Crohns disease * Heart failure * Kidney failure * Cirrhosis or liver disease * Osteoporosis * Blood clotting disorder * Visual problems * Low albumin * Low BMI * Specific medications \*Diabetes drug treatment is allowed except for short-acting insulin, long-acting insule more than 15 units daily, pioglitazone, rosiglitazone, orlistat, acarbose, miglitol or voglibose.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00782795